Cytosorbents Corp Stock Price, News & Analysis

CytoSorbents Corporation (NASDAQ: CTSO) has announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021. CEO Dr. Phillip Chan will engage in a fireside chat with Danielle Antalffy, highlighting the company's progress and future outlook. CytoSorbents specializes in critical care immunotherapy and its flagship product, CytoSorb®, is widely used for blood purification in critically ill patients. The technology is approved in the EU and has been utilized in over 121,000 treatments globally.

CytoSorbents Corporation (NASDAQ: CTSO) has received recognition from the UK's National Institute for Health and Care Excellence (NICE) regarding its CytoSorb blood purification technology. The Medtech Innovation Briefing highlights the ability of CytoSorb to reduce bleeding risks in cardiac surgery by eliminating the blood thinner ticagrelor. NICE's analysis indicates potential cost savings of £3,941 per procedure and shorter hospital stays. Dr. Efthymios Deliargyris noted its game-changing potential, emphasizing the importance of strong clinical evidence for adoption.

CytoSorbents Corporation (NASDAQ: CTSO) announced the appointment of David D. Cox, Ph.D., MBA, as Vice President of Global Regulatory Affairs. Dr. Cox, who previously held a similar role at Integra LifeSciences, has extensive experience in regulatory approvals, including FDA submissions for medical devices. His primary focus will be to expedite U.S. FDA approval for CytoSorb's use in removing ticagrelor during cardiac surgery, a process that has received Breakthrough Device designation. This leadership change is expected to enhance regulatory strategy and facilitate entry into the lucrative U.S. market.

CytoSorbents Corporation (NASDAQ: CTSO) has received approval from the Korean Ministry of Food and Drug Safety for its CytoSorb blood purification technology. This approval allows treatment for various conditions, including cytokine storms, liver disease, and trauma, in a healthcare system serving nearly 52 million people. This marks a significant milestone in expanding CytoSorb's reach, now available in 67 countries. The partnership with Fresenius Medical Care Korea aims to enhance critical care and addresses rising sepsis mortality rates in the region.

CytoSorbents Corporation (NASDAQ: CTSO) has received Health Canada authorization for its CytoSorb® blood purification technology for use in COVID-19 patients. CytoSorb is now commercially available in Canada and has received approvals in 67 countries worldwide. This authorization allows for emergency use in hospitalized COVID-19 patients under Interim Order ID# 316575. The company collaborates with ebbtides medical to expedite availability across Canada as COVID-19 cases rise. CytoSorb is designed to treat inflammation, enhancing outcomes in critical care and cardiac surgery.

CytoSorbents Corporation (NASDAQ: CTSO) has pre-announced record preliminary unaudited financial results for Q4 2020 and full-year 2020, highlighting a significant 73% revenue growth. The company reported approximately $40.8 million in total revenue for 2020, compared to $24.9 million in 2019. Q4 2020 revenue reached about $11.8 million, up from $7.4 million in Q4 2019. CytoSorb treatments exceeded 121,000, reflecting strong demand, especially during the COVID-19 pandemic. The company ended the year with a robust cash balance of over $71 million.

CytoSorbents Corporation (NASDAQ: CTSO) has appointed James Komsa as the new Vice President of U.S. Sales and Marketing. Komsa, a veteran from Medtronic with over 18 years of experience, previously led multiple divisions generating substantial annual sales. He aims to enhance the CytoSorb brand and focus on expanding its critical care applications, particularly for ticagrelor removal in cardiothoracic surgeries. The company is targeting a potential $250 million U.S. market as it leverages FDA Emergency Use Authorization for COVID-19 treatments.

CytoSorbents Corporation (NASDAQ: CTSO) announced that Health Canada has granted Medical Device Authorization for the emergency use and sale of CytoSorb in hospitalized COVID-19 patients. This authorization allows for the therapy's distribution in Canada and expands its reach to 67 countries worldwide. CytoSorbents aims to collaborate with ebbtides medical to ensure rapid availability of the treatment. The authorization is valid until Fall 2021 but may be renewed based on public health needs. CytoSorb has previously received U.S. FDA Emergency Use Authorization.

CytoSorbents Corporation (NASDAQ: CTSO) has appointed Dr. Christian Steiner as Executive Vice President - Sales and Marketing. With over nine years at the company, Dr. Steiner has been pivotal in establishing CytoSorb as a market leader, contributing to more than $100 million in cumulative sales. Currently, the company boasts an annualized revenue run rate exceeding $40 million, with CytoSorb treatments delivered to over 110,000 patients across 66 countries. Dr. Steiner's leadership is expected to further enhance growth and innovation in critical care immunotherapy.